TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01692002

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium propionate
Description: Sodium propionate capsule or tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Placebo capsule or tablet

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Oral glucose tolerance test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous glucose tolerance test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous glucose tolerance test.
Study: NCT00818207

Intervention type: OTHER
Group type: OTHER
Intervention: Full Smoking Cessation Treatment Coverage (100%)
Description: This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.

Intervention type: OTHER
Group type: OTHER
Intervention: No Smoking Cessation Treatment Coverage (0%)
Description: None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
Study: NCT03258632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)
Description: Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
Study: NCT03411577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Study: NCT04172701

Intervention type: DRUG
Intervention: Long-acting Muscarinic Antagonists (LAMA)
Description: drug

Intervention type: DRUG
Intervention: Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)
Description: drug
Study: NCT03185234

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: 2 mA, 10 min, 5 sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham stimulation, 10 min, 5 sessions
Study: NCT03297528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
Study: NCT03820934

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibroscan and Fibrosure
Description: Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
Study: NCT02363608

Intervention type: OTHER
Intervention: standard post surgery care

Intervention type: BEHAVIORAL
Intervention: Caring Canine program
Description: The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.

Intervention type: BEHAVIORAL
Intervention: Caring Canine program
Description: The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.

Intervention type: BEHAVIORAL
Intervention: baseline and post assessment
Description: The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
Study: NCT00451308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of labor with foley balloon - 60cc of saline
Description: 60 cc of fluid
Study: NCT02168881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Study: NCT00451308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction of labor with foley balloon with 30cc
Description: 30cc of saline in foley
Study: NCT04995991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRT rhythm only
Description: RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRT rhythm + visual cue
Description: RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
Study: NCT00376727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: molecular diagnostic method
Description: Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Peripheral Blood Mononuclear Cells (PBMC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Cetuximab Pharmacodynamics
Study: NCT03267108

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INOpulse®
Description: Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Open Label Extension
Description: Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
Study: NCT04242719

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic stimulation
Description: Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic stimulation
Description: Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: About 20 ml of blood was drawn from the patient's antecubital vein and inserted into two 10-ml vacutainer tubes that contain trisodium citrate (T-LAB PRP Kit, T-Biyoteknoloji, Bursa, TURKEY). These tubes were placed in a refrigerated (+4 °C) centrifuge (Nüve NF 1200R, Nüve Laboratuar Teknolojileri, Ankara, TURKEY) and spun at 2500 rpm (580×g) for 8 min within 30 min of collection. Three different layers formed in the tubes: red blood cells at the bottom, platelet-rich plasma in the middle, and platelet-poor plasma in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe and immediately injected into the sub-tenon space of each eye after topical anesthesia with proparacaine hydrochloride (Alcaine, Alcon, USA) drops.
Study: NCT01149226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloral hydrate
Description: 30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chloral hydrate
Description: 30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
Study: NCT03307967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT-PM
Description: SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
Study: NCT00496652

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
Study: NCT02717585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure Therapy (CPAP)
Description: Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
Study: NCT02166905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given via intracutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given via intracutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC
Study: NCT03484091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyruan-One
Description: single dose intra-articular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: single dose intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: single dose intra-articular injection
Study: NCT04262622

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group TEA: thoracic epidural analgesia group
Description: in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group RSB: rectus sheath block group
Description: Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
Study: NCT06434259

Intervention type: DEVICE
Intervention: Digi-physical support system
Description: A support system named Evira will be used to provide behavioral treatment.
Study: NCT01160978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80mg
Description: The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Rx
Description: The transplant recipients who have received an organ from non-treated donors.
Study: NCT03220360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect pulp capping
Description: Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct pulp capping
Description: Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vital pulpotomy
Description: Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
Study: NCT02044705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active and Healthy Families
Description: Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
Study: NCT01670240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02975505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strict blood pressure control
Description: Systolic Blood Pressure Target \< 120 mm Hg (measured at home)
Study: NCT03773692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive feedback and JITAI
Description: Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA.
Study: NCT00418015

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood for OPRM1 analysis

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood for OPRM1 analysis
Study: NCT04377672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 Human Convalescent Plasma
Description: 1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL.
Study: NCT03095716

Intervention type: OTHER
Intervention: laparoscopic surgery
Description: Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
Study: NCT01509872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused Cognitive Behavioral Therapy
Description: 9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Friendly Space
Description: 9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
Study: NCT01237028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
Study: NCT02235402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendrofluazide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03686696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI
Description: Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI
Description: Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB
Description: Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB
Description: Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
Study: NCT02856022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical ilioinguinal nerve stimulation
Description: Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1\~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Irrigation
Description: The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
Study: NCT01586689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oxford House
Description: community-based recovery home for participants recovering from substance dependency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Haven
Description: professionally-staffed treatment facility

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual aftercare
Description: control group - participants may or may not seek treatment on their own